# Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

> **NCT06452316** · PHASE1 · RECRUITING · sponsor: **Claris Biotherapeutics, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Limbal Stem Cell Deficiency

## Interventions

- **BIOLOGICAL:** CSB-001 Ophthalmic Solution 0.1%

## Key facts

- **NCT ID:** NCT06452316
- **Lead sponsor:** Claris Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06452316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06452316, "Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06452316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*